申请人:The Scripps Research Institute
公开号:US20040002528A1
公开(公告)日:2004-01-01
Analogs of the antitumor antibiotics CC-1065 and the duocarmycins incorporate the 1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) alkylation subunit. The CBI-based analogs have potent cytotoxic activity and are useful as efficacious antitumor compounds. A direct relationship between functional stability and in vitro cytotoxic potency is disclosed. The CBI-based analogs are easily synthesized and are 4× more stable and 4× more potent than the corresponding analogs containing the authentic CPI alkylation subunit of CC-1065 and comparable in potency to agents containing the authentic alkylation subunit of duocarmycin SA. Similarly, the CBI-based agents alkylate DNA with an unaltered sequence selectivity at an enhanced rate and with a greater efficiency than the corresponding CPI analog and were comparable to the corresponding analog incorporating the duocarmycin SA alkylation subunit. Systematic and extensive modifications and simplifications in the DNA binding subunits attached to CBI are also described.
抗肿瘤抗生素CC-1065和Duocarmycins的类似物包含1,2,9,9a-四氢环丙[c]苯[e]吲哚-4-酮(CBI)烷基化亚单位。基于CBI的类似物具有强效的细胞毒性活性,可用作有效的抗肿瘤化合物。揭示了功能稳定性和体外细胞毒性效力之间的直接关系。基于CBI的类似物易于合成,比含有CC-1065的真实CPI烷基化亚单位的相应类似物稳定性和效力高4倍,并与含有Duocarmycin SA真实烷基化亚单位的药物效力相当。同样,基于CBI的药物以不改变序列选择性的增强速率和更高效率烷基化DNA,并与相应的CPI类似物相当,并与包含Duocarmycin SA烷基化亚单位的相应类似物相当。还描述了附加到CBI的DNA结合亚单位的系统性和广泛性修改和简化。